1
Clinical Trials associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
100 Clinical Results associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)
100 Translational Medicine associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)
100 Patents (Medical) associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)
100 Deals associated with URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)